Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05686161
Other study ID # SWC310-1
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date October 19, 2022
Est. completion date June 27, 2023

Study information

Verified date October 2022
Source Stemirna Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary#Objectives #Immunogenicity:To demonstrate the non-inferiority of binding antibody response in terms of geometric mean titers (GMT) of mRNA vaccine compare with mRNA COVID-19 vaccine(Pfizer) 14 days post dose. Secondary#Immunogenicity: 1. To describe binding antibody profile at D01, D29 and D181 of each study group. 2. To describe the neutralizing antibody profile at D15, D29 and D181 of each study intervention group. Secondary#Safety: To assess the reactogenicity and safety of a booster dose in a heterologous vaccination regimen in subjects previously immunized with two Sinopharm doses. Exploratory#Cell-mediated immunity: To describe the cellular immune response profile at D01, D08, D15, in a subset of 30 participants for each study group. Exploratory#Efficacy: To describe theoccurrence ofvirologically-confirmedCOVID-19 like illness and serologicallyconfirmed SARS-CoV-2 infection.


Description:

Endpoint: Immunogenicity Endpoints: GMT of Anti-Spike IgG antibody titers will be measured with the ELISA assay on D01, D15. Immunogenicity Endpoints: Binding antibody titers to full length SARS-CoV-2 Spike (S) protein will be measured for each study intervention group with the ELISA method. 1. Antibody titer on D01, D29, D181. 2. Fold-rise in antibody titer at D15, D29 and D181 relative to D01Neutralizing antibody titers will be measured with the neutralization assay. 3. Antibody titer on D15, D29 and D181. 4. Fold rise in serum neutralization titer [post/pre] relative to D01 at D15, D29 and D181. Safety Endpoints: 1. Occurrence of local and systemic AEs reported within 7 days after study vaccination (per group); 2. Occurrence of unsolicited AEs reported within 28 days after study vaccination (per group); 3. Occurrence of SAEs and AESIs within 28 days after study vaccination (per group). Exploratory#Cell-mediated immunity Endpoints: INF-γ will be measured in whole blood and/or cryopreserved PBMC following stimulation with pools of S-antigen peptides. Exploratory#Efficacy Endpoints Occurrence of confirmed symptomatic cases during the study period


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 600
Est. completion date June 27, 2023
Est. primary completion date December 7, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Participant is willing and able to give written informed consent for participation in the study. 2. Male or Female, aged 18 years or above and in good health as determined by study clinician. 3. Female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunization continuously until 3months after boost immunization. 4. In the Investigator's opinion, is able and willing to comply with all trial requirements. 5. Subjects had completed the 2-dose series vaccination of COVID-19 inactivated vaccine(Sinopharm) at least 24 weeks with the completed the 2-dose Series as the primary vaccination according to the product label. Exclusion Criteria: - The participant may not enter the study if ANY of the following apply: 1. Confirmed cases, suspected cases or asymptomatic cases of COVID-19; 2. Self-reported history of SARS and MERS infection; 3. Receipt of live attenuated vaccine within one month prior to vaccination and other vaccines within 14 days prior to vaccination; 4. Receipt of any SARS-COV-2 vaccine after last dose of primary vaccination 5. Participants who are pregnant at enrolment or planning to become pregnant during the first 3 months following vaccination 6. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccines 7. History of allergic disease or reactions likely to be exacerbated by any component of study vaccines 8. Any history of anaphylaxis to any component of vaccine. 9. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or continuous use of anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran, edoxaban), or prior history of significant bleeding or bruising following IM injections or venipuncture 10. Suspected or known current alcohol or drug dependency 11. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data 12. Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness (mild/moderate well controlled comorbidities are allowed) 13. Scheduled elective surgery during the trial 14. Other reasons investigators did not consider it appropriate to refer to clinical trials

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
SW-BIC-213;SARS-Cov-2.
The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows: Subjects (N˜600) Group 1: (N˜200) - Stemirna(SW-BIC-213) Group 2: (N˜200) - Pfizer(BNT162b2) Group 3: (N˜200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life.
Sinopharm (BIBP);SARS-Cov-2.
The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows: Subjects (N˜600) Group 1: (N˜200) - Stemirna(SW-BIC-213) Group 2: (N˜200) - Pfizer(BNT162b2) Group 3: (N˜200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life.
Pfizer(BNT162b2);SARS-Cov-2.
The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows: Subjects (N˜600) Group 1: (N˜200) - Stemirna(SW-BIC-213) Group 2: (N˜200) - Pfizer(BNT162b2) Group 3: (N˜200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life.

Locations

Country Name City State
Lao People's Democratic Republic Savannakhét Provincial hospital Savannakhét Sava

Sponsors (1)

Lead Sponsor Collaborator
Stemirna Therapeutics

Country where clinical trial is conducted

Lao People's Democratic Republic, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunogenicity GMT of Anti-Spike IgG antibody titers will be measured with the ELISA assay on day1 , day 15 day1, day15
See also
  Status Clinical Trial Phase
Recruiting NCT05073744 - Nalbuphine Versus Morphine for Perioperative Tumor Ablation Phase 4
Completed NCT03969641 - Safety of RIV4 Versus IIV4 in Pregnant Women Phase 4
Completed NCT05592951 - Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers N/A
Completed NCT04693429 - Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01243502 - A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers Phase 1
Completed NCT06072170 - Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience Phase 1
Completed NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Recruiting NCT06060379 - Giochiamo 626 - Gaming for Health and Safety in Workplaces N/A
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Completed NCT05188638 - Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects Phase 1
Completed NCT05145621 - Oral Bio-equivalence Study Phase 1
Recruiting NCT05580159 - New Generation mRNA Booster Vaccine Against Emerging VOCs Phase 3
Not yet recruiting NCT04596956 - Safety and Efficacy of Sodium Bicarbonate Ringer Injection Phase 4
Completed NCT03033329 - Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4 Phase 1
Terminated NCT01929811 - NeoMET Study in Neoadjuvant Treatment of Breast Cancer Phase 2
Completed NCT01193335 - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants. Phase 4
Completed NCT03300466 - A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds N/A
Recruiting NCT06046053 - MATRIX-002: Trial to Assess Acceptability and Safety of Two Placebo Vaginal Films Early Phase 1